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Résumé en
anglais
OBJECTIVE: Temozolomide (TMZ) is an alkylating agent frequently used in well-
differentiated metastatic pancreatic neuroendocrine tumors (PNETs) with very
variable responses. O-methylguanine-DNA methyltransferase (MGMT) is a DNA
repair enzyme whose loss of expression has been suggested to be predictive of
response to TMZ in various human tumors. We evaluated the predictive value of
MGMT status, assessed by immunohistochemistry (IHC) and methylation-specific PCR
(MS-PCR), in well-differentiated metastatic PNETs treated by a TMZ-based
chemotherapy.
PATIENTS AND METHODS: All patients with metastatic PNETs treated with TMZ-
based chemotherapy between 2010 and 2016 in two academic centers, for whom the
tumor samples were available, were included. Clinical data were collected and the
MGMT status of the tumors was analyzed using MS-PCR and IHC.
RESULTS: Twenty-two patients (nine men, median age 61 years) were included. The
loss of MGMT protein expression detected by IHC was observed in 13 (59%) patients
and MGMT promoter hypermethylation was detected by MS-PCR in three (15%) out
of 20 interpretable cases. MGMT status did not correlate significantly with the best
radiological response according to the Response Evaluation Criteria In Solid Tumors
criteria or with progression-free survival. There was no correlation between MGMT
protein expression and MGMT gene promoter methylation.
CONCLUSION: These results indicate that a deficient MGMT status in PNETs,
determined by loss of protein expression in IHC or by the presence of MGMT gene
promoter methylation measured by MS-PCR, is not associated with a better response
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